Abivax SA (ABVX)

Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)

Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX) PR...

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to...

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a...

Abivax Announces Results of its May 11, 2026 Annual General Meeting

Abivax Announces Results of its May 11, 2026 Annual General Meeting PARIS, France – May 11, 2026 – 10:05 pm...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B7 - Prospectus [Rule 424(b)(7)]

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American...

Abivax to Present Data on Obefazimod at Digestive Disease Week®

Abivax to Present Data on Obefazimod at Digestive Disease Week® Presentations Highlight Comprehensive...

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026Availability of the Preparatory...

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]